Trial Profile
Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine (DAC) Administered Alone or in Combination With the Histone Deacetylase Inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in Patients > 60 Years With Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2023
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Tretinoin (Primary) ; Valproic acid (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DECIDER
- 13 Dec 2022 Results assessing genetic and epigenetic changes at secondary resistance after continued treatment, presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results of post-hoc analysis determining the predictive impact of TP53 status, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 08 Dec 2020 Results of exploratory subgroup analysis assessing activity of Decitabine (DAC) combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology